TLDR: Twin Health has successfully closed a $53 million Series E funding round, led by Maj Invest, to significantly expand its AI digital twin platform. This investment will accelerate the company’s reach among health plans and Fortune 500 clients, enhancing its innovative approach to managing and reversing chronic metabolic conditions like diabetes and obesity through personalized, data-driven care without relying on high-cost medications.
Twin Health, a pioneering metabolic health company based in Mountain View, California, has announced a substantial $53 million Series E funding round. The investment, spearheaded by Maj Invest of Denmark, with continued participation from existing investors Iconiq and Temasek, values the company at over $950 million. This significant capital injection is earmarked to accelerate Twin Health’s expansion efforts, particularly among health plans and Fortune 500 clients across diverse sectors including retail, healthcare, financial services, technology, and manufacturing.
The core of Twin Health’s breakthrough lies in its real-time AI digital twin technology. This innovative platform creates a unique digital replica for each member, constructed from thousands of individual data points encompassing biomarkers, behaviors, and personal preferences. These insights reflect not only a member’s metabolism but also their habits in nutrition, sleep, and physical activity. By understanding how an individual’s body responds to lifestyle choices, the AI digital twin provides continuous, personalized recommendations on nutrition, activity, sleep, and stress.
This advanced AI model is seamlessly integrated with dedicated human care teams, offering comprehensive, high-performance support for metabolic health. Members receive daily personalized guidance and live coaching to achieve specific health goals, such as lowering A1C levels, achieving healthier weight targets, or safely transitioning off medications. The human care teams provide continuous, clinically guided support that adapts to members’ needs in real time, ensuring round-the-clock accessibility.
Jahangir Mohammed, founder and CEO of Twin Health, emphasized the company’s distinct approach: “Traditional solutions have focused on just managing the disease. Twin is different. The AI digital twin guides members using their own data, not population averages, in a way that is precise, engaging, and sustainable. This model provides continuous, 24/7 guidance to meet the reality that metabolic health is a continuous condition, not an episodic event.” This philosophy underscores Twin Health’s commitment to addressing the root causes of metabolic diseases to improve and reverse conditions like type 2 diabetes, prediabetes, and obesity.
The funding follows the publication of a landmark study in the New England Journal of Medicine Catalyst, which concluded that Twin Health’s AI digital twin is a highly effective treatment for diabetes and weight loss, often without the need for high-cost medications. Jeppe Christianson, CEO of Maj Invest, highlighted the global impact of metabolic diseases, stating, “Diabetes and obesity are among the world’s biggest health challenges. For decades, we have invested in solutions to address the epidemic of metabolic disease. Twin Health represents a paradigm shift in diabetes and obesity care—one that is precise to each individual and scalable for employers and health plans.”
Also Read:
- Hello Patient Raises $22.5 Million Series A to Expand AI-Powered Healthcare Communications
- Reveal HealthTech Secures $7.2 Million Series A Funding to Advance AI in Healthcare
Twin Health operates on a performance-based care framework, offering results-driven pricing for employers and health plans. Clients only pay when members achieve specific clinical outcomes, such as A1C reduction, weight loss, or medication elimination. This model has demonstrated strong market validation, with impressive retention metrics reporting over 90% member retention and less than 1% voluntary churn.
